Astellas Pharma has been granted a patent for antibodies targeting CLDN6, aiding in cancer diagnosis and determining CLDN6 expression in cancer cells. The patent covers specific amino acid sequences for antibody heavy and light chain variable regions. GlobalData’s report on Astellas Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Astellas Pharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Astellas Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Astellas Pharma's grant share as of February 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies for diagnosing cancer by detecting cldn6 expression

Source: United States Patent and Trademark Office (USPTO). Credit: Astellas Pharma Inc

A recently granted patent (Publication Number: US11919951B2) discloses an antibody or antigen-binding fragment that specifically binds to claudin 6 (CLDN6). The antibody comprises specific amino acid sequences in the heavy chain variable region (VH) and light chain variable region (VL), as detailed in the patent claims. The antibody is designed to target cell surface membrane-bound CLDN6, particularly on cancer cells, including ovarian, testicular, stomach, breast, pancreatic, lung, uterine, and urinary bladder cancer cells, as well as metastatic cancer cells.

Furthermore, the patent claims cover various aspects of the antibody, including its chimeric or humanized forms, monoclonal nature, and binding specificity to CLDN6 epitopes. The patent also extends to diagnostic test kits containing the antibody with detectable labels for identifying CLDN6, as well as conjugates of the antibody coupled to labels for various detection methods. The patent emphasizes the potential applications of the antibody in cancer diagnosis and treatment, highlighting its specificity and binding characteristics. Overall, the patent provides a detailed framework for the development and use of the antibody targeting CLDN6, offering a promising avenue for cancer research and therapy.

To know more about GlobalData’s detailed insights on Astellas Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies